Antibody-enhanced COVID-19 vaccination

Description of the granted funding

A major challenge in COVID-19 vaccinations is to induce robust and good-quality protective immunity, especially in older persons. We will use a clinically approved therapeutic antibodies to overcome these limitations in experimental models. By co-injecting small quantities of immunomodulatory antibodies with the with a vaccine antigen we will revive the COVID-19 vaccine responses in aged immune system, and re-direct the anti-vaccine immune response to the most beneficial protecting direction. Our conceptually new way of using accepted therapeutic antibodies as COVID-19 vaccine adjuvants has the potential to generate more effective vaccine responses with less adverse effects, substantial vaccine-sparing and the protection of older individuals.
Show more

Starting year

2020

End year

2022

Granted funding

Marko Salmi Orcid -palvelun logo
531 859 €

Funder

Research Council of Finland

Funding instrument

Targeted Academy projects

Other information

Funding decision number

336422

Fields of science

Biomedicine

Research fields

Biolääketieteet

Themes

Lisätalousarvio III 2020

Identified topics

covid, pandemic, vaccines